DURECT Co. (NASDAQ:DRRX) Short Interest Update

DURECT Co. (NASDAQ:DRRX) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 809,100 shares, a drop of 6.9% from the January 15th total of 868,800 shares. Based on an average daily volume of 103,200 shares, the short-interest ratio is currently 7.8 days. Approximately 2.9% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

DRRX has been the subject of several recent analyst reports. StockNews.com assumed coverage on shares of DURECT in a report on Saturday. They issued a “sell” rating for the company. HC Wainwright restated a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

DURECT Stock Performance

DRRX traded up $0.02 during trading on Monday, reaching $0.77. 39,218 shares of the company traded hands, compared to its average volume of 63,170. DURECT has a 12-month low of $0.70 and a 12-month high of $1.88. The firm has a fifty day simple moving average of $0.83 and a 200 day simple moving average of $1.12. The company has a market cap of $23.87 million, a P/E ratio of -1.26 and a beta of 0.91.

Institutional Trading of DURECT

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in shares of DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 14,658 shares during the last quarter. Jane Street Group LLC lifted its position in DURECT by 266.0% during the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 28,486 shares during the last quarter. Finally, Richmond Brothers Inc. grew its stake in shares of DURECT by 12.2% in the 4th quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock worth $961,000 after buying an additional 138,920 shares in the last quarter. 28.03% of the stock is currently owned by institutional investors.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.